Article Text

Download PDFPDF
192 Tacrolimus-induced chronic inflammatory demyelinating polyradiculoneuropa- thy (CIDP): a case series
  1. Matthew Evans1,2,
  2. Sam Dahdaleh1,
  3. Kushan Karunaratne1,
  4. Jane Pritchard1,
  5. Simon Rinaldi3,
  6. Stuart Viegas1
  1. 1Imperial College Healthcare
  2. 2Imperial College London
  3. 3University of Oxford

Abstract

Introduction Calcineurin inhibitors are used for immunosuppression after solid organ transplantation, and tacrolimus is the most commonly agent used. It is associated with several adverse effects including oppor- tunistic infection, nephrotoxicity, diabetes and increased cancer risk, but less well known is its association with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Case series: We describe 7 cases of patients developing CIDP following tacrolimus treatment post transplantation. There were 3 cardiac, 3 lung and 2 renal transplants. Time since starting tacrolimus to development of CIDP varied widely from 5 months to 14 years. All cases were clinically consistent with CIDP with demyelinating neuropathy on neurophysiology. Intravenous immunoglobulin (IVIg) was tried in 6/7 cases but only showed clinical effec- tiveness in 2 patients, who required long-term treatment 2-monthly while continuing tacrolimus. In 3 of the IVIg non-responders (and 1 patient not trailed on IVIg), immunosuppression was switched to an alternative agent (sirolimus) with long-term resolution of neuropathy. Some cases were confounded: 1 associated with EBV and another CMV viraemia.

Conclusion Various case reports have demonstrated a possible association between tacrolimus and CIDP, but this is the largest case series to date. IVIg responsiveness alone is generally poor, but resolution is possible when switching to alternative agents.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.